Eisai's EA Pharma, Newron In Agreement For Evenamide In Japan And Other Asian Territories

RTTNewsDec 13 07:55 ET

Newron Pharmaceuticals Signs Schizophrenia Drug License Deal in Japan, Asia

MT NewswiresDec 13 01:45 ET

Stocks that moved the day before part 1: Perseus, Symphony Technology, Japan Micronics, ETC.

Stock name <code> Closing price on the 12th ⇒ Change from the previous day Cell source <4880> 1052 +30 Collaborated with Docomo, agreed to consider collaboration with Japan Post. Digi HD <3676> 830 +362 Financial Estimates for the period ending March 2025 have been revised downward for revenue but upward for net profit estimates. P-Ban <3559> 382 +17 Announced a forecast for the dividend for the period ending March 2025, which was initially undecided, to be 10 yen, an increase of 2 yen from the previous period. Silver Life <9262> 724 -45 First quarter operating profit decreased by 29.4%. Perseus.

Fisco JapanDec 12 17:15 ET

Jefferies Adjusts Eisai's Price Target to 4,200 Yen From 5,500 Yen, Keeps at Hold

MT NewswiresDec 12 02:34 ET · Ratings

Afternoon session [Active stocks and traded stocks]

*Cell Source <4880> 1052 +30 Cooperation with Docomo, reached agreement for cooperation consideration with Japan Post. *Dejiha HD <3676> 830 +3623 Sales revenue Financial Estimates for the fiscal year ending March 2025 have been downwardly revised, but net profit Financial Estimates have been upwardly revised. *Pivan <3559> 382 +17 Announced that the previously undecided Dividends for the fiscal year ending March 2025 are expected to be 10 yen, an increase of 2 yen compared to the previous period. *Silver Life <9262> 724 -45 First quarter operating profit decreased by 29.4%. *Perseus <4882> 663 -

Fisco JapanDec 12 02:10 ET

12/12 [Today's Investment Strategy]

[FISCO Specially Selected Brand] [Material Brand] Pharma Foods ＜2929＞ 958 yen (12/11) Mainly sells supplements and cosmetics. They also work on functional materials. First quarter financial results have been announced. Operating profit was 0.882 billion yen (up 46.7% from the same period last year). The cumulative number of shipments of “Pneumo Hair Growth Agent” has exceeded 29 million units as of November 19. Other product groups emphasized profitability indicators, and advertising costs were suppressed. Operating profit for the fiscal year ending 25/7 is expected to be 2 billion yen (down 60.9% from the previous fiscal year)

Fisco JapanDec 11 19:00 ET